KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $961.3 million.

  • BeOne Medicines' Cash from Financing Activities rose 749178.64% to $961.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $958.0 million, marking a year-over-year increase of 7577.28%. This contributed to the annual value of $193.4 million for FY2024, which is 5355.12% down from last year.
  • BeOne Medicines' Cash from Financing Activities amounted to $961.3 million in Q3 2025, which was up 749178.64% from $35.0 million recorded in Q2 2025.
  • BeOne Medicines' Cash from Financing Activities' 5-year high stood at $3.3 billion during Q4 2021, with a 5-year trough of -$110.4 million in Q4 2022.
  • Over the past 5 years, BeOne Medicines' median Cash from Financing Activities value was $35.0 million (recorded in 2025), while the average stood at $267.9 million.
  • In the last 5 years, BeOne Medicines' Cash from Financing Activities crashed by 16385.62% in 2023 and then surged by 749178.64% in 2025.
  • Quarter analysis of 5 years shows BeOne Medicines' Cash from Financing Activities stood at $3.3 billion in 2021, then tumbled by 103.36% to -$110.4 million in 2022, then skyrocketed by 414.45% to $347.0 million in 2023, then crashed by 101.3% to -$4.5 million in 2024, then skyrocketed by 21352.97% to $961.3 million in 2025.
  • Its last three reported values are $961.3 million in Q3 2025, $35.0 million for Q2 2025, and -$33.8 million during Q1 2025.